What the FDA labels say about taking them together
Cilastatin/imipenem/relebactam and valproic acid
Cilastatin/imipenem/relebactam's FDA label of December 9, 2025 names valproic acid in its drug interactions section; the valproic acid label PlainMeds reads does not name cilastatin/imipenem/relebactam. The cilastatin/imipenem/relebactam label: “DRUG INTERACTIONS Ganciclovir: Avoid concomitant use. Valproic Acid or Divalproex Sodium:”
Check it at the source: the cilastatin/imipenem/relebactam FDA label on DailyMed (effective December 9, 2025, Merck Sharp & Dohme LLC); the valproic acid FDA label on DailyMed (effective January 24, 2025, PAI Holdings, LLC dba PAI Pharma).
What does the cilastatin/imipenem/relebactam label say about valproic acid?
Cilastatin/imipenem/relebactam label, drug interactionsDRUG INTERACTIONS Ganciclovir: Avoid concomitant use. ( 7.1 ) Valproic Acid or Divalproex Sodium:
Cilastatin/imipenem/relebactam label, warnings and precautionsIf focal tremors, myoclonus, or seizures occur, evaluate patients, to determine whether RECARBRIO should be discontinued. ( 5.2 ) Increased Seizure Potential Due to Interaction with Valproic Acid:
Source: FDA drug label (RECARBRIO), Merck Sharp & Dohme LLC, effective December 9, 2025 (SPL set be32f468-738b-40df-a425-591e12f65159), via openFDA; the full label on DailyMed
What does the valproic acid label say about cilastatin/imipenem/relebactam?
Valproic acid's label (effective January 24, 2025) does not name cilastatin/imipenem/relebactam in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VALPROIC ACID), PAI Holdings, LLC dba PAI Pharma, effective January 24, 2025 (SPL set 7d5cb52e-37dd-4dfa-a6f4-09f9548846c6), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cilastatin/imipenem/relebactam | Valproic acid | |
|---|---|---|
| Labeled for | Urinary tract infections | Seizures and epilepsy, Migraine |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.243 per capsule 250 mg capsule |
| Shortage now | A presentation being discontinued | Listed; available |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once